EVH · Evolent Health, Inc.
$3.65
+0.19 (+5.49%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$408.14M
Shares
113.06M
Volume · Oct 5
1.34M
Avg daily vol (3M)
2.99M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.46
Open$3.42
Day$3.32–3.58
52W close$2.17–8.25
Avg vol 30d2.4M
Short int14.1M · 12.4% float · 5.8d
Short vol48%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.10B
Trailing 12 months
Net income (TTM)
−$504.99M
Trailing 12 months
Revenue growth YoY
+46.9%
Year over year
Operating margin
-20.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-2.9%
Year over year · fewer shares
Price change (1Y)
-56.1%
Trailing year
Short interest
12.4%
Latest settlement · 5.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
−13%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
21%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
+37%
trailing
YTD return
−14%
this year
Relative strength
+25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +37 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.44% of float · ▼ -9.1% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
199 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−2%
Y/Y
EPS growth
−526%
Y/Y
Free cash flow
$3.3M
Balance sheet
$818.7M
net debt
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Full Year 2026
Adjusted EBITDA
Non-GAAP
Initiated
$120M – $135M
2026
Cash for capitalized software development
$25M – $30M
2027
Adjusted EBITDA
Non-GAAP
$150M
Guided vs delivered
· last 3 settled
Total revenue
full year
guided $845M – $880M
$907.96M
Beat +5.3%
Total revenue
second quarter
guided $210M – $225M
$222.06M
In line
Total revenue
first quarter
guided $205M – $215M
$215.07M
Beat +2.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
21%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +37 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.44% of float · ▼ -9.1% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
199 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 21%
Range high $8
vs 200-day avg -10%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $28.05M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss attributable to common shareholders of Evolent Health, Inc. -28.36M
-703K Interest income
+16.86M Interest expense
+2.72M Benefit from (provision for) income taxes
+21.57M Depreciation and amortization expenses
+0K Extinguishment of Series A Preferred Stock and other refinancing fees
+41K Gain (loss) from equity method investees
+0K Loss on option exercise
+0K Change in fair value of contingent consideration
-109K Other income (expense), net
+0K Loss on lease termination
+15.2M Stock-based compensation expense
+275K Severance costs
+0K Dividends and accretion of Series A Preferred Stock
+569K Transaction-related costs
= Adjusted EBITDA 28.05M
|
|||
| Average Lives on Platform - Administrative Services | 1.19M | the three months ended June 30, 2026 filing | — |
| Average Lives on Platform - Performance Suite | 6.72M | the three months ended June 30, 2026 filing | — |
| Average Lives on Platform - Specialty Technology and Services Suite | 75.64M | the three months ended June 30, 2026 filing | — |
| Average PMPM Fees - Administrative Services | $13.46 | the three months ended June 30, 2026 filing | — |
| Average PMPM Fees - Performance Suite | $24.05 | the three months ended June 30, 2026 filing | — |
| Average PMPM Fees - Specialty Technology and Services Suite | $0.34 | the three months ended June 30, 2026 filing | — |
| Average Unique Members | 39,956 | Q2 2026 | — |
| Cases - Cases | 12K | the three months ended June 30, 2026 filing | — |
| Medical Expense Ratio | 95.3% | Q2 2026 | — |
| Medical Expense Ratio excluding Evolent Care Partners non-GAAP | 95.3% | Q2 2026 | — |
| Performance Suite revenue excluding revenue from Evolent Care Partners non-GAAP | $484.5M | the three months ended June 30, 2026 filing | — |
| Revenue per Case - Cases | $3,608 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EVH
this stock
Evolent Health, Inc.
|
$408.14M | -13.5% | -1.8% | — | 12.4% |
|
VEEV
Veeva Systems Inc
|
$45.44B | +22.4% | +28.1% | 45.9 | 3.1% |
|
TEM
Tempus AI, Inc.
|
$15.34B | +29.8% | +83.4% | — | 15.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.20B | -29.7% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.02B | +60.9% | +28.2% | 33.8 | 5.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EVH | -4.2% | -18.8% | +36.8% | -0.9% | -13.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -3.9% | -18.3% | +24.6% | -1.8% | -26.4% |